Eli Lilly (LLY)
Develops cardiometabolic, cancer, immunology, and neuroscience medicines led by tirzepatide.
$1,147.89
vs last close−17.00 (−1.46%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9,499 | 9,353 | 8,768 | 11,303 | 11,439 | 13,533 | 12,729 | 15,558 | 17,601 | 19,292 | 19,799 | 22,974 |
| Cost of revenue | 1,860 | 1,788 | 1,674 | 2,170 | 2,171 | 2,404 | 2,225 | 2,448 | 3,008 | 3,372 | 3,577 | 3,268 |
| Gross profit | 7,639 | 7,565 | 7,095 | 9,133 | 9,268 | 11,129 | 10,504 | 13,110 | 14,593 | 15,920 | 16,222 | 19,706 |
| 4,098 | 4,372 | 4,359 | 4,714 | 4,834 | 5,447 | 5,202 | 6,089 | 6,206 | 6,933 | 6,444 | 7,249 | |
| Research & development | 2,409 | 2,563 | 2,523 | 2,711 | 2,734 | 3,023 | 2,734 | 3,336 | 3,466 | 3,802 | 3,510 | 3,819 |
| 1,688 | 1,810 | 1,836 | 2,003 | 2,100 | 2,425 | 2,468 | 2,753 | 2,741 | 3,131 | 2,934 | 3,430 | |
| Selling & marketing | 0 | 0 | 0 | 0 | 0 | 0 | −1 | 0 | 0 | 0 | 0 | 0 |
| General & administrative | 1,688 | 1,810 | 1,836 | 2,003 | 2,100 | 2,425 | 2,469 | 2,753 | 2,741 | 0 | 0 | 0 |
| Operating income | 3,541 | 3,193 | 2,736 | 4,419 | 4,434 | 5,682 | 5,302 | 7,021 | 8,386 | 8,987 | 9,778 | 12,457 |
| −3,114 | −684 | −200 | −901 | −2,846 | −643 | −1,846 | −244 | −1,154 | −721 | −928 | −3,210 | |
| Interest income | 49 | 45 | 46 | 37 | 48 | 44 | 48 | 40 | 65 | 0 | 0 | 0 |
| Interest expense | 125 | 138 | 180 | 184 | 193 | 225 | 244 | 249 | 180 | 123 | 332 | 345 |
| Other non-operating income | 2,989 | 546 | 20 | 718 | 2,653 | 419 | 0 | 0 | 974 | −2,571 | 0 | 0 |
| Income before tax | 427 | 2,509 | 2,536 | 3,517 | 1,588 | 5,039 | 3,456 | 6,777 | 7,232 | 8,266 | 8,850 | 9,247 |
| Income tax expense | 485 | 319 | 293 | 550 | 618 | 629 | 697 | 1,116 | 1,650 | 1,629 | 1,454 | 2,152 |
| Net income from continuing operations | −57 | 2,190 | 2,243 | 2,967 | 970 | 4,410 | 2,759 | 5,661 | 5,583 | 6,638 | 7,396 | 7,095 |
| Net income | −57 | 2,190 | 2,243 | 2,967 | 970 | 4,410 | 2,759 | 5,661 | 5,583 | 6,638 | 7,396 | 7,095 |
| EPS, basic | −$0.06 | $2.43 | $2.49 | $3.29 | $1.08 | $4.91 | $3.07 | $6.30 | $6.23 | $7.42 | $8.28 | $7.96 |
| EPS, diluted | −$0.06 | $2.42 | $2.48 | $3.28 | $1.07 | $4.88 | $3.06 | $6.29 | $6.21 | $7.39 | $8.26 | $7.94 |
| Weighted average shares, basic | 949 | 899 | 901 | 901 | 901 | 898 | 898 | 898 | 897 | 898 | 895 | 892 |
| Weighted average shares, diluted | 949 | 904 | 904 | 904 | 905 | 903 | 901 | 900 | 899 | 898 | 896 | 894 |
| EBITDA | 963 | 3,035 | 3,116 | 4,115 | 2,248 | 5,748 | 5,765 | 7,499 | 7,882 | 12,145 | 10,287 | 12,991 |
| Depreciation & amortization | 411 | 388 | 401 | 414 | 467 | 485 | 463 | 478 | 470 | 586 | 509 | 534 |
| EBIT | 552 | 2,647 | 2,716 | 3,701 | 1,781 | 5,263 | 5,302 | 7,021 | 7,412 | 11,559 | 9,778 | 12,457 |